Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Associates

Neither a doctor nor a teaching hospital

Research payments

$11,243,033

980 payments

Through program year 2025, Clinical Research Associates is reported as receiving $11,243,033 in research payments, across 980 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,211,958 352
2024 Research $1,345,513 430
2023 Research $1,138,434 99
2022 Research $2,685,124 32
2021 Research $3,592,402 36
2020 Research $1,221,822 21
2019 Research $47,780 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $5,136,699 19 payments
  2. Pfizer Inc. $4,024,331 77 payments
  3. Seqirus USA Inc $1,230,304 792 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $602,895 50 payments
  5. Roche Diabetes Care, Inc. $103,272 4 payments
  6. Rapid Pathogen Screening, Inc. $60,220 5 payments
  7. Ironwood Pharmaceuticals, Inc $42,944 7 payments
  8. Merck Sharp & Dohme Corporation $14,839 6 payments
  9. Novartis Pharmaceuticals Corporation $7,065 3 payments
  10. Allergan Inc. $6,634 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $4,131,187 8 payments
  2. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $4,017,235 68 payments
  3. The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod $724,870 4 payments
  4. A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $573,579 238 payments
  5. The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older $528,760 453 payments
  6. Obesity Long term safety in patients with CV risk $371,904 1 payment
  7. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $230,990 49 payments
  8. A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States $129,920 2 payments
  9. Compliance of People with Type 2 Diabetes on Non-Insulin Anti-diabetic Therapy with the Data Input Requirement For the Clarity Insulin-Chek App $103,272 4 payments
  10. The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do not achieve control with high dose inhaled corticosteroid ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibody therapy $98,736 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record